Investigating bleeding adverse events associated with BTK inhibitors in the Food and Drug Administration adverse event reporting system (FAERS)

Background This study analyzed the bleeding adverse events (AEs) resulting from the treatment of B-cell lymphoma with Bruton tyrosine kinase (BTK) inhibitors, according to reports in the US Food and Drug Administration's Adverse Event Reporting System (FAERS)